Novo Nordisk’s Alhemo Gains the CHMP’s Positive Opinion as a Prophylatic Treatment of Hemophilia A or B
Shots:
-
The CHMP has recommended Alhemo (QD, SC) as a prophylactic treatment of hemophilia A/B with inhibitors in patients (≥12yrs.), with the EC’s decision anticipated within ~2mos.
-
The opinion was based on the P-III (explorer7) study assessing the efficacy & safety of Alhemo to treat haemophilia A or B with inhibitors. Alhemo will be available in a convenient, pre-mixed, and prefilled pen upon approval
-
Alhemo (concizumab) is a mAb that blocks anti-tissue factor pathway inhibitor (TFPI) for thrombin production, preventing blood clotting
Ref: Novo Nordisk | Image: Novo Nordisk
Related News:- Novo Nordisk’s Awiqli Receives the CHMP’s Positive Opinion for the Treatment of Diabetes
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
A passionate content writer with expertise in delivering high-quality and engaging content, Dipanshu is a keen reader and a versatile writer. Dipanshu dedicatedly covers news ranging from biopharma, life sciences, biotech, and MedTech to diagnostics and animal health companies, FDA, EMA, and biosimilar approvals. He can be contacted at connect@pharmashots.com
